EUVIMEDEUVIMED entdecken
Crossref

Elevated estradiol with prolonged mifepristone to treat progesterone-receptor positive meningioma

Devora A. Aharon, Olivia J. Carpinello, Lauren A. Bishop, Alan H. DeCherney

Global Reproductive Health · 2018

DOI: 10.1097/grh.0000000000000019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global Reproductive Health, 2018. Verfasst von Devora A. Aharon und 3 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To report a finding of persistently elevated estradiol (E2) after prolonged mifepristone use for treatment of progesterone-receptor positive meningioma, an association which has not previously been reported.

Design

This is a case report.

Setting

Outpatient Reproductive Endocrine clinic at a tertiary referral center. Case Report: A 48-year-old gravida 1 para 0-0-1-0 with progesterone-receptor positive meningioma, recurrent after multiple debulking surgeries. Patient was treated with mifepristone for 11 years with symptomatic improvement and tumor shrinkage. Levels of follicle-stimulating hormone, luteinizing hormone, and estradiol (E2) were followed throughout the patient’s course of mifepristone therapy. E2 levels were found to be persistently elevated to 500–700 pg/mL. Materials and Methods: Enhanced E2 assay, a liquid-chromatography tandem mass spectrometry (LC-MS/MS) based assay, was measured simultaneously with the routinely used immunoassay for 5 years in attempt to obtain a more accurate assessment.

Results

E2 levels using the standard immunoassay were found to be persistently elevated while the patient was taking mifepristone. Using the enhanced LC-MS/MS assay, E2 was initially elevated, however was subsequently low. After the patient discontinued the medication, E2 levels as measured by the immunoassay normalized.

Conclusions

Prolonged mifepristone use was found to be associated with markedly elevated E2 levels in our patient. If this is a true elevation, it may help explain the incidence of endometrial hyperplasia and endometrial polyps with prolonged mifepristone use. However, this was likely a false elevation, potentially due to cross-reactivity of mifepristone with the immunoassay, given the normal values obtained with the enhanced LC-MS/MS E2 assay. Whether prolonged mifepristone use may cause true or falsely elevated E2 in a wider population, and the mechanism through which it does so, should be further investigated.

Zitieren

APA

Aharon, D. A., Carpinello, O. J., Bishop, L. A., & DeCherney, A. H. (2018). Elevated estradiol with prolonged mifepristone to treat progesterone-receptor positive meningioma. Global Reproductive Health. https://doi.org/10.1097/grh.0000000000000019

Vancouver

Aharon DA, Carpinello OJ, Bishop LA, DeCherney AH. Elevated estradiol with prolonged mifepristone to treat progesterone-receptor positive meningioma. Global Reproductive Health. 2018. doi:10.1097/grh.0000000000000019

BibTeX
@article{Aharon2018,
  author = {Aharon, Devora A. and Carpinello, Olivia J. and Bishop, Lauren A. and DeCherney, Alan H.},
  title = {Elevated estradiol with prolonged mifepristone to treat progesterone-receptor positive meningioma},
  journal = {Global Reproductive Health},
  year = {2018},
  doi = {10.1097/grh.0000000000000019}
}
Kostenlos starten →